GRIN Therapeutics, Inc.
PrivateLast Round
Series D
May 28, 2025
Total Funding Raised
$140M
Company Overview
GRIN Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops precision therapies for pediatric neurodevelopmental disorders. The company's primary focus is on its lead investigational drug, radiprodil, a negative allosteric modulator that selectively targets the GluN2B subunit of the NMDA receptor. This drug is being developed to treat GRIN-related neurodevelopmental disorder (GRIN-NDD), as well as other conditions like tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD). Founded in 2021, the company is an affiliate of Neurvati Neurosciences and a portfolio company of Blackstone Life Sciences. GRIN Therapeutics has received significant funding, including a $140 million Series D financing in May 2025, to advance radiprodil into a global Phase 3 clinical trial. The company has also entered a strategic collaboration with Angelini Pharma for the commercialization of radiprodil outside of North America.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GRIN Therapeutics, Inc. Comps
Public and private peers based on sector, stage, and business model.
GRIN Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | May 28, 2025 |
GRIN Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Blackstone Life Sciences | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 11, 2025
Partnered with InformedDNA to offer free genetic counseling to US patients.
- Dec 5, 2025
Presenting novel rating scales for GRIN-NDD at AES Annual Meeting.
GRIN Therapeutics, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about GRIN Therapeutics, Inc.'s valuation, stock price, and market status.
